Khaled Abousaleh
07. 04. 21

Zynnon welcomes Prof. Dr. Christoph Schankin as Chief Medical Officer

Schindellegi, Switzerland, April 7th, 2021

Zynnon is pleased to announce that Prof. Dr. med. Christoph Schankin has joined the company as Chief Medical Officer and a member of the Management Team.

For almost 20 years, Christoph has been involved as the principal investigator in international and national clinical trials. He has served as an advisor for many pharmaceutical companies, and has published more than 100 original research articles, reviews and book chapters.

After completing his medical training at the University of Heidelberg, University of York, and Columbia University, he specialised in Neurology at the University of Munich with a focus on headache, intensive care medicine, acute neurology, epilepsy, and general neurology.

During a post-doctoral fellowship at the University of California, San Francisco (UCSF), he performed extensive clinical research in human models of migraine and was the first to describe the migraine-related visual disturbance, “visual snow syndrome“.

Christoph is Professor of Neurology at the University of Bern and consultant neurologist at Inselspital, Bern University Hospital.

Khaled Abousaleh, CEO of Zynnon comments: “I’m very pleased to welcome Professor Schankin to our Management Team. Christoph has many years of experience and brings extensive knowledge of clinical trials and the medical community in Europe, as well as in the United States.”

Prof. Dr. med. Christoph Schankin
Prof. Dr. med. Christoph Schankin

About Zynnon:

Zynnon ( is a start-up focused on improving and protecting people’s health using the Internet of Medical Things (IoMT). Zynnon’s mission is to provide AI-driven data analytics solutions for the consumer health market based on data insights gathered from our network of connected medical devices.

Its first product line, Lieberty, will combine affordable high-tech medical devices with associated services and solutions to protect people during viral outbreaks by reducing the risk of infection. Designed and manufactured in Switzerland, Lieberty’s cordless non-contact temperature screening devices will allow businesses and communities to resume their regular pre-pandemic activities with a significantly higher level of safety.

For further information:

Zynnon AG

Juliana Acosta

Office Manager & Head of Communications